Invested by Aleph SpotitEarly CEO Shlomi Madar on How Their Dogs Can Sniff Early-Stage Cancer, Why Dogs + AI is a Critical Combination, and Whether Cancer Screening Should be Regulated
Feb 4, 2026
Dr. Shlomi Madar, a PhD-trained molecular biologist and CEO of SpotitEarly building canine+AI cancer screening, explains how trained beagles sniff VOCs from breath in three minutes. He discusses why dogs plus machine learning boost accuracy, plans for direct-to-consumer $250/year kits, and regulatory and clinical validation challenges for scaling this approach.
AI Snips
Chapters
Transcript
Episode notes
Stronger Signals At Earlier Stages
- SpotitEarly reports slightly better sensitivity at early stages versus late stages, possibly due to tumor microenvironment masking.
- The team calls this a repeating but still-hypothesized pattern requiring more research.
Validate With Clinics And CLIA First
- Conduct rigorous clinical trials and secure CLIA certification before market launch.
- Use hospital collaborations to validate clinical utility and scale responsibly.
Target Outreach To Underserved Groups
- Market screening tests by targeting populations with low screening uptake and access barriers.
- Combine online outreach with community events and advocacy-group partnerships.